Synergistic Gene Delivery Platforms

Integrating self-replicating cell selective gene delivery compositions with AI, IoT, blockchain, and novel materials to create powerful, personalized gene therapy systems

Despite advances in gene therapy, existing approaches often lack precision, efficiency, and scalability. The original patent's self-replicating cell selective gene delivery compositions addressed some of these limitations, but further integration with distinct technologies is needed to unlock full potential. The new inventive concept bridges this gap by combining the original patent's technology with AI, IoT, blockchain, and novel materials to create a more effective and personalized gene delivery system

The new inventive concept integrates the original patent's self-replicating cell selective gene delivery compositions with AI modules for optimizing gene expression, IoT-enabled sensors for real-time monitoring, blockchain-based health record systems for secure data storage and sharing, and nanoparticle-based delivery systems incorporating novel materials for enhanced biocompatibility and targeted cellular uptake. These synergistic combinations enable personalized gene therapy, improved gene editing efficacy, and decentralized gene regulation. The AI module analyzes real-time cellular response data to optimize gene expression, while the IoT-enabled sensors provide continuous monitoring of gene expression and editing efficacy. The blockchain-based health record system ensures secure storage and sharing of gene expression data, and the nanoparticle-based delivery system enhances targeted cellular uptake and biocompatibility

The new claims introduce novel synergistic combinations of the original patent's technology with AI, IoT, blockchain, and novel materials, providing a more effective, personalized, and secure gene delivery system. The inventive step lies in the unexpected integration of these distinct technologies to create a more powerful and efficient gene therapy platform

Alternative embodiments may include integrating the gene delivery composition with other AI algorithms, such as machine learning or deep learning, or using different types of IoT-enabled sensors or blockchain-based systems. Variations may include using different novel materials for the nanoparticle-based delivery system or incorporating additional technologies, such as CRISPR-Cas9 gene editing, to further enhance the gene therapy platform

The new inventive concept has significant commercial potential in the gene therapy market, particularly in the areas of personalized medicine, gene editing, and decentralized health data management. Target industries include biotechnology, pharmaceuticals, and healthcare, with potential applications in cancer treatment, rare genetic disorders, and regenerative medicine